Blog

Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of traditional and psychedelics as a therapeutic, today announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting autoimmune diseases. “We are delighted to expand our partnership with UMB. Pre-clinical testing of these peptides has shown positive results in animal studies. The three-phage peptides we identified specifically target inflamed vascular endothelium of arthritic joints in an adjuvant-induced arthritis rat model. To test the therapeutic effect of the peptides, arthritic Lewis rats (n=4/group)…

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its subsidiary Numinus Bioscience Inc. has filed a patent application to the World Intellectual Property Organization (WIPO), an agency of the United Nations, for a rapid production process for Psilocybe and other fungi species containing psilocybin and other compounds. A provisional patent application for the process was submitted to the United States Patent & Trademark Office (USPTO) on June 24, 2021. With this additional filing, international patent protection would extend to all WIPO member states that…

There are only two more episodes of season one left of the Psychedelic Invest Podcast. We certainly hope you’ve subscribed by now. On the ninth episode of the Psychedelic Invest Podcast, Kimberly Stuck of Allay Consulting joins to talk about regulation and compliance in both the cannabis and psychedelics industries.  During the conversation, host Bruce Eckfedlt asks the hard-hitting questions we all want to know about the future of plant medicines.  New episodes of the podcast are released weekly. Stay tuned and subscribe to be notified when a new episode is published. This podcast is available on Apple Podcasts, Spotify,…

Many people use our Neuly psychedelic database and platform to research the many psychedelic compounds that are receiving press and buzz. Of course, there are some that are more popular than others. But what people may overlook, may be the right fit for them. After all, there is a myriad of benefits spanning all available psychedelic compounds. Why limit your knowledge to only those that you hear about most? On Wednesday, Mindshifting Moments hopes to pull back the curtain a bit further on ibogaine. You may have heard of it, but do you really know how it heals? Margaret Williamson…

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBED), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC. “We are pleased to have the opportunity to team up with the Clearway network and in particular with Dr. Fred Sancilio, a global expert in drug development and strategic planning. Dr. Sancilio brings over 40 years of pharmaceutical experience to our program and has a track record of success that is unmatched”. Philip Young, CEO of Lobe Dr. Fred D. Sancilio,…